HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Bolufer, P. Articles by Sanz, M. A. Search for Related Content PubMed PubMed Citation Articles by Bolufer, P. Articles by Sanz, M. A. Related Collections Molecular Diagnostics and Genetics Automation and Analytical Techniques

Quantitative Assessment of PML-RARa and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial

¹ Molecular Biology, Department of Medical Biopathology, Hospital Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain;² Hematopathology Unit, Hospital Clínic, Barcelona, Spain;³ Molecular Biology, Hematology, Hospital Gran Canaria Dr. Negrin, Las Paslmas de GC, Spain;⁴ Molecular Biology, Hematology, Hospital 12 de Octubre, Madrid, Spain;⁵ Immunopathology and Molecular Biology, Hematology, Hospital Clínico Universitario, Salamanca, Spain;⁶ Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;⁷ Laboratory of Cytogenetics and Molecular Biology, Service of Pathology, Hospital del Mar, Barcelona, Spain;⁸ Laboratory of Integrated Diagnosis of Oncohematologic Diseases, University Tor-Vergata, Rome, Italy;⁹ Laboratorio di Diagnostica Molecolare Oncoematologica, Dipartimento di Biotecnologie Cellulari ed Ematologia, Universitá degli Studi "La Sapienza", Rome, Italy;¹⁰ Biology, Hematology, Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain;¹¹ Molecular Cytogenetic Unit, Servicio de Hematologia, Hospital Universitario Puerta de Hierro, Madrid, Spain;¹² Unified Laboratory, Immunology, Hospital Donostia, San Sebastian, Gupuzcoa, Spain;¹³ Molecular Medicine Unit-INGO (Sergas), University of Santiago de Compostela, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain;¹⁴ Departamento de Estadistica e Investigación Operativa, Universidad Politécnica de Valencia, Valencia, Spain;¹⁵ Clinical Hematology, Service of Hematology, Hospital Universitario La Fe, Hospital Universitario La Fe, Valencia, Spain

^aauthor for correspondence: fax 34961973030, e-mail bolufer_pas@gva.es

The first 20% of the full text of this article appears below.

The recent introduction on the market of instruments for real-time PCR has prompted the development of quantitative assays for the most common fusion transcripts detectable in hematologic malignancies. However, because the ABI PRISM apparatus (ABI; Applied Biosystems) was the first available instrument for real-time PCR, most of the methods developed for the ABI PRISM use TaqMan probe chemistry (1)(2)(3). With the introduction of other real-time PCR instruments, such as the LightCycler (LC; Roche), other methods have been described (4)(5)(6)(7). The instruments differ in several respects, including the light sources and the approach to acquisition of fluorescence data. Few reports have compared the results obtained with different types of real-time PCR instruments (8). To the best of our knowledge, no such multicenter studies with common calibrators and common methods have been reported.

In the present study we analyzed the results obtained with two of the more widely used instruments for real time PCR, i.e., the ABI and LC, for amplifying two rearrangements frequently detectable in human leukemia, the BCR-ABL and PML-RARa fusion genes. For BCR-ABL several quantitative methods have been established for both instruments (3)(4)(5)(6)(7), whereas for PML-RARa most of the quantitative methods have been developed for the ABI PRISM (1).

The quantification of BCR-ABL transcripts is clinically relevant for monitoring patients with chronic myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation (4)(9) or treatment with interferon-a or imatinib mesylate (9)(10)(11). For example, low numbers of BCR-ABL transcripts after 2 weeks of imatinib treatment predict a good response to imatinib after 4 weeks (9. . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				T. Zhang, S. Grenier, B. Nwachukwu, C. Wei, J. H. Lipton, S. Kamel-Reid, and the Association for Molecular Pathology Hematopath Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease Monitoring: Summary and Recommendations J. Mol. Diagn., September 1, 2007; 9(4): 421 - 430. [Abstract] [Full Text] [PDF]